These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36388348)

  • 21. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of inactivated COVID-19 in healthy adults aged ≥ 18 years: A passive surveillance in Indonesia.
    Kaswandani N; Medise BE; Leonard E; Satari HI; Sundoro J; Hadinegoro SRH; Putra A; Angkasa PF
    PLoS One; 2023; 18(10):e0286484. PubMed ID: 37824453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Yang H; Li Z; Zhang R; Guo S; Wang B; Fang X; Zhang D; Zhang X; Tong Y; Wang Q; Deng Q; Sun Z; Liu X; Gao Y
    Vaccine; 2023 Feb; 41(7):1354-1361. PubMed ID: 36658045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
    Huang J; Zhang MQ; Huang MZ; Lin GM
    Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.
    Zhang DS; Bao XP; Zhu JJ; Zheng WJ; Sun LX
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116253. PubMed ID: 38507964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety of delayed vaccination with the national immunization program vaccines in children aged 0-6 years from 2019 to 2021 in Xuhui District, Shanghai City in China].
    Wu QS; Mao SQ; Xu Y; Gong RJ; Zhou Q; Liu M; Liu JY; Zhu DH; Guo X
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jul; 57(7):983-991. PubMed ID: 37482734
    [No Abstract]   [Full Text] [Related]  

  • 29. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series.
    Hidayat R; Diafiri D; Zairinal RA; Arifin GR; Azzahroh F; Widjaya N; Fani DN; Mesiano T; Kurniawan M; Al Rasyid ; Giantini A; Haris S
    Curr Neurovasc Res; 2021; 18(3):360-363. PubMed ID: 34579636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.
    Adhikari S; Maharjan J; Bhattarai S; Kunwar K; Agrawal S; Dangal RK; Chapagain RH; Bista TB; Bhattarai S
    J Nepal Health Res Counc; 2024 Mar; 21(4):651-658. PubMed ID: 38616598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana.
    Marfoh K; Samba A; Okyere E; Acheampong F; Owusu E; Darko DNA; Zakariah J; Mensa H; Aidoo E; Mohammed Y
    BMJ Open; 2023 Jun; 13(6):e061643. PubMed ID: 37380201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parental perspectives of vaccine safety and experience of adverse events following immunisation.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Baghurst P
    Vaccine; 2013 Apr; 31(16):2067-74. PubMed ID: 23422146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais.
    Silva RBD; Silva TPRD; Sato APS; Lana FCF; Gusmão JD; Souza JFA; Matozinhos FP
    Rev Saude Publica; 2021; 55():66. PubMed ID: 34706042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.
    Mangat HS; Musah A; Luedtke S; Syed AA; Maramattom BV; Maruthanal J; Bosman A; Kostkova P
    Front Public Health; 2022; 10():972464. PubMed ID: 36311588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.
    Romero-Ibarguengoitia ME; González-Cantú A; Pozzi C; Levi R; Mollura M; Sarti R; Sanz-Sánchez MÁ; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; Del Rio-Parra GF; Barco-Flores IA; González-Facio R; Azzolini E; Barbieri R; de Azevedo Dias AR; Henriques Guimarães Júnior M; Bastos-Borges A; Acciardi C; Paez-Bo G; Teixeira MM; Rescigno M
    Front Immunol; 2022; 13():894277. PubMed ID: 35967368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.